Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Small Pharma Inc V.DMT

Healthcare
Small Pharma Inc. is a biotechnology company focused on short-duration psychedelic therapies for mental health conditions. The Company is focused on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions that are scalable, commercially differentiated, and conveniently dosed, with the goal of addressing key unmet needs in the treatment of... see more

Recent & Breaking News (TSXV:DMT)

Small Pharma to Present at Cowen's 43rd Annual Health Care Conference

GlobeNewswire March 1, 2023

First Subject Dosed in Small Pharma's First-in-Human Phase I Clinical Trial with SPL028

GlobeNewswire February 15, 2023

Small Pharma (TSXV:DMT) adds two new patents to its portfolio approved for issue

Jonathon Brown February 1, 2023

Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

GlobeNewswire February 1, 2023

Small Pharma Reports Fiscal Third Quarter 2023 Highlights

GlobeNewswire January 25, 2023

Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

GlobeNewswire January 25, 2023

Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

GlobeNewswire January 24, 2023

First Patient dosed in Small Pharma's (TSXV:DMT) Phase I study

Brieanna McCutcheon  January 9, 2023

First Patient Dosed in Small Pharma's Phase I Study Exploring Intramuscular Administration of SPL026

GlobeNewswire January 9, 2023

Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

GlobeNewswire December 22, 2022

First Patient Dosed in Small Pharma's Drug Interaction Study

GlobeNewswire December 15, 2022

Small Pharma To Support University College London Research Project on Neuroplasticity

GlobeNewswire December 14, 2022

Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium

GlobeNewswire December 8, 2022

Small Pharma to Participate in November Investor and Healthcare Conferences

GlobeNewswire November 11, 2022

Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028

GlobeNewswire October 31, 2022

Small Pharma (TSXV:DMT) granted second U.S. patent

John Ballem  October 19, 2022

Second United States Patent Granted for Small Pharma's Psychedelics Portfolio

GlobeNewswire October 19, 2022

Small Pharma Reports Fiscal Second Quarter 2023 Highlights

GlobeNewswire October 14, 2022

Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder

GlobeNewswire September 19, 2022

Small Pharma Enters Into Automatic Share Purchase Plan

GlobeNewswire September 13, 2022